19 results about "Cell replacement" patented technology

This utility model discloses a battery structure for easy cell replacement, including a top cover and several stacked side-opening support shells. The top cover covers the top of the stacked side-opening support shells. Each side-opening support shell consists of a cell protective ring shell and a bottom liquid cooling plate installed at the bottom of the cell protective ring shell. A cell replacement port is provided on one side of the cell protective ring shell. A cell heat-conducting support frame is provided at the bottom of the shell cavity of each side-opening support shell. The cell heat-conducting support frame extends to the outside of the cell protective ring shell through the cell replacement port and is equipped with a side hole baffle. A cell assembly is mounted on the cell heat-conducting support frame via a core frame. A notch-filling edging strip is installed on the top of the side hole baffle. A notch-filling edging strip is provided on the top of the outer side of the cell protective ring shell. The advantages are: through the side-pull structure and sliding components, the cells of the stacked battery packs can be quickly replaced without disassembling the upper stacked battery pack, making it convenient and practical.

This invention proposes a voltage allocation method for a dual-track standard cell library, comprising: a sensitivity-based coarse cell replacement, which calculates the replacement sensitivity of each cell based on its delay and power consumption, and replaces some high-voltage cells in the circuit with low-voltage cells in descending order of replacement sensitivity, resulting in a target chip where the estimated delay margin value for each path is the minimum positive value; and a path-based fine cell adjustment, which classifies each path and the cells in each path in the target chip, and then performs cell replacement adjustment, eliminating timing violations while further reducing the occurrence of low-voltage cells driving high-voltage cells, resulting in a target chip where the accurate delay margin value for each path is the minimum positive value, while minimizing circuit power consumption.

The present invention relates to a system (1) which is developed for providing artificial intelligence and machine learning-aided cell change in beyond 5G and 6G mobile communication networks.

This utility model provides a functional battery cell tray quick-release structure, including an outer frame, inner linings, and two-color buckles. Two inner linings are symmetrically placed on the left and right sides inside the outer frame, each detachably connected to a row of two-color buckles. A left battery cell clamping cavity is formed between adjacent two-color buckles on the left inner lining, and a right battery cell clamping cavity is formed between adjacent two-color buckles on the right inner lining. The left and right battery cell clamping cavities respectively clamp the left and right ends of the battery cell. The two-color buckle includes a buckle frame, an outer soft rubber layer, and an inner soft rubber layer. The outer soft rubber layer is integrally disposed on the outside of the buckle frame, and the inner soft rubber layer is integrally disposed on the inside of the buckle frame. The outer and inner soft rubber layers are different colors, and a portion of the inner soft rubber layer extends towards the rear of the buckle frame to form a press handle. The use of detachable two-color buckles allows for compatibility with battery cells of different thicknesses by replacing the buckles. The press handle design enables quick cell replacement, minimizing labor costs and improving replacement efficiency.

The application provides a midbrain organoid and a preparation method and application thereof. The midbrain organoid is obtained in vitro by using pluripotent stem cells, can simulate the development and maturation rules of nerve cells in vivo, provides a solid foundation for later researches such as building a drug screening platform and modeling of diseases related to dopaminergic neurons, and opens up a new way for cell replacement therapy.

The purpose of this invention is to solve the problem that existing battery boxes use adhesive to fix battery cells and weld electrical connections, making it difficult to disassemble and replace the battery cells. This invention provides a battery box structure and method that facilitates battery cell replacement. The battery box structure includes a box body, battery cells, clips, sheet metal, connectors, and a power board. The box body has an internal cavity, and the battery cells are housed within it. The sheet metal is fixed inside the box body, and the clips engage with the sheet metal, with the upper end of the clips pressing down on the battery cells to achieve adhesive-free fixing. The connectors are made of conductive material and are located between the electrodes of adjacent battery cells. Each connector includes a cut section and connecting sections on both sides of the cut section, with the connecting sections on both sides fixedly connected to the corresponding electrodes of the two battery cells. The power board is used to electrically connect the two connecting sections after the cut section is removed. By using clips to fix the battery cells without adhesive, and in conjunction with the cuttable connectors, a detachable electrical connection is achieved, enabling rapid individual replacement of the battery cells.

A method for treating hearing loss in a subject in need thereof is provided. The method includes providing a combination of transcription factors to induce generation of a hair cell-like cell, thereby treating the hearing loss in the subject. The generated hair cell-like cells exhibit characteristic of mature functional cells that is useful in cell replacement therapy for autologous transplantation.

The invention discloses a combined cell transplantation system for Huntington's disease treatment, a preparation method and application. The invention belongs to the technical field of biomedicine, and aims at solving the problems that when an existing stem cell transplantation technology is used for treating the Huntington's disease (HD), the graft survival rate is low, differentiation uncertainty is high, and integration with a host neural network is difficult. The combined cell transplantation system for treating the Huntington's disease comprises human umbilical cord mesenchymal stromal cells (hUC-MSCs) and striatum organoid (hStrOs), the human umbilical cord mesenchymal stromal cells play a role in immunoregulation and provide endogenous immune microenvironment support, and the human umbilical cord mesenchymal stromal cells play a role in immunoregulation and provide endogenous immune microenvironment support; the striatum organ takes medium spinous projective neurons (MSNs) for expressing DARPP-32 and CTIP-2 as a main body, and undertakes a cell replacement function. The HD cell therapy is promoted to be converted from a traditional single cell replacement mode to an'immune regulation-nerve regeneration 'multi-dimensional functional remodeling mode through cooperation of the HD cell therapy and the Huntington's disease, and a new way is provided for cell therapy of the Huntington's disease.

The application belongs to the technical field of regenerative medicine, and discloses a kind of organoid culture method derived from human and non-human primate subventricular zone neural stem cells. By optimizing the medium formula and regulating transcription factors, the organoid is successfully induced to differentiate into CRABP1-expressing neuronal precursors. These cells express TAC3, and the application overcomes the limitations of existing technologies in simulating primate-specific neural lineages and complex brain structures, providing a breakthrough in vitro model for studying neural development, neurological diseases and drug development. The established system not only provides a new tool for studying the development of primate nervous system and disease mechanism, but also provides a reliable experimental platform and transplantable cell source for developing targeted drugs, constructing advanced disease models and conducting cell replacement therapy.

The invention belongs to the technical field of regenerative medicine, and discloses an organoid culture method derived from neural stem cells in subventricular regions of human and non-human primates. By optimizing a culture medium formula and regulating and controlling transcription factors, the organoid is successfully induced to be differentiated into the neuron precursor for expressing the CRABP1. The cell expresses TAC3, the limitation of the prior art in simulation of special neuropedigree and complex brain structure of primates is overcome, and a breakthrough in-vitro model is provided for research on neurodevelopment and nervous system diseases and drug development. The established system not only can provide a new tool for researching the development law and disease mechanism of the primate nervous system, but also can provide a reliable experimental platform and a transplantable cell source for developing targeted drugs, constructing advanced disease models and developing cell replacement therapy.

This invention discloses an Isl1-mimicking polypeptide, TAT-Isl1-ELE-1, containing 40 amino acids and consisting of a TAT sequence that promotes polypeptide entry into cells, a linker peptide, and a target sequence. The target sequence is amino acids 121-141 of the human Isl1 protein. The TAT-Isl1-ELE-1 polypeptide possesses Isl1-like functions and can effectively reprogram mouse spinal cord reactive astrocytes into motor neuron-like cells. Based on the amino acid sequence and spatial structure of this polypeptide, a novel small molecule drug can be designed, which can be synthesized in large quantities and is easy to operate clinically. This provides a new and viable approach for cell replacement therapy and regenerative medicine research after spinal cord injury (SCI), thereby achieving better SCI repair and functional reconstruction effects.

The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a culture medium for inducing mesenchymal cells to differentiate into insulin-secreting cells and application of the culture medium. By accurately regulating and controlling the oxidation-reduction state of NAD < + > / NADH in cells, the composition proportion of exogenous fatty acid, the dynamic supply concentration of glucose and the anti-oxidative stress level, the differentiation efficiency is remarkably improved, the induction period is shortened, and the method is suitable for industrial production on the premise of not depending on recombinant protein induction factors such as Activin A and Wnt3a. And a mature beta-like cell with stable glucose stimulus dependent insulin secretion (GSIS) capability is obtained. The kit is especially suitable for human adipose tissue-derived mesenchymal stem cells, and can be used as an independent kit product for preclinical research and drug screening of diabetes cell replacement therapy.

A method for treating hearing loss in a subject in need thereof is provided. The method includes providing a combination of transcription factors to induce generation of a hair cell-like cell, thereby treating the hearing loss in the subject. The generated hair cell-like cells exhibit characteristic of mature functional cells that is useful in cell replacement therapy for autologous transplantation.

This invention provides a non-human vertebrate exhibiting a higher human liver cell growth rate, a higher human liver cell replacement rate, and higher histological-physiological human reproducibility than existing non-human vertebrates comprising the human liver transplanted therein and a method for producing such non-human vertebrate. Specifically, the method for producing a transgenic non-human vertebrate comprising human liver cells transplanted therein comprises transplanting human liver cells in a non-human vertebrate that has impaired or lowered immune reactions against humans in the presence of human IL-6 in vivo.

Provided herein are peptide amphiphiles (PAs) and supramolecular PA nanostructures that mimic glial derived neurotrophic factor (GDNF), a growth factor that induces neuronal survival, maturation, and increased electrical activity. In particular, injectable biomaterials comprising GDNF mimetic PAs are provided, as well as methods of using GDNF mimetic PAs for the treatment or prevention of neurological injuries, diseases, and disorders, including concurrently with cell replacement therapy.

Disclosed are lung progenitor cells and methods of generating the lung progenitor cells starting from mammalian pluripotent stem cells. The lung progenitors can be used as therapeutic treatments for various pulmonary disorders or injuries. The lung progenitor cells may also be used to model lung diseases / conditions and screen for desired agents.

The invention discloses a chemical small molecule composition for inducing directional differentiation of umbilical cord mesenchymal stem cells into dopaminergic neurons, a culture medium, an induction method and application. The chemical small molecule composition is prepared from SB431542, LDN193189, CHIR99021, Forskolin, Y27632, FGF8 (Fibroblast Growth Factor 8), SHH (Secret Hormone Hormone) and DAPT (Diaminopropyltriethoxysilane). A chemical reprogramming method without gene integration is established through combination of small molecule compounds and morphogenetic factors, human umbilical cord mesenchymal stem cells are efficiently induced and differentiated into dopaminergic neurons, and a safe, stable and clinically convertible functional cell source is provided for cell replacement treatment of Parkinson's disease. According to the scheme, the problems of tumorigenicity, ethical limitation, immunological rejection and the like in a traditional induction method are solved, and a new technical path and a new cell preparation strategy are provided for stem cell treatment of neurodegenerative diseases.

Described herein are chemically defined methods for differentiation of midbrain dopaminergic cells (mDACs). Also described herein are improved monolayer-based methods for differentiation of mDACs. Further provided herein are quality control criteria that can determine the standards of safety and efficacy for generation of clinical-grade mDACs.

The invention discloses a functional islet organ in-vitro culture system without complex equipment dependence and a preparation process, and belongs to the field of regenerative medicine and cell therapy. According to the system, bone marrow mesenchymal stem cells (BMSCs) of 7-day-old SD suckling rats are used as seed cells, optimally prepared porcine pancreatic tissue lysis buffer is used as a core inducer, and a DMEM basal culture medium containing 10% of fetal calf serum and 1% of penicillin-streptomycin and a special auxiliary reagent are matched; the core inducer is prepared through a standardized process, and the validity period is 1 year; the preparation process comprises four core processes of inoculation, induction, liquid change in stages and harvesting, the steps of passage and cryopreservation can be selected, and the mature pancreas islet organs can be obtained in 22 days in a conventional cell laboratory. According to the method, expensive reagents and complex equipment are not needed, operation is easy and convenient, cost is low, repeatability is high, a renewable pancreas islet source is provided for replacement treatment of type 1 diabetes cells, the method can also be used as an ideal in-vitro model for screening of anti-diabetic drugs and research of a pancreas islet development mechanism, and the scientific research value and clinical transformation potential are remarkable.